Invicta eshre-poster-pregnancy rate after frozen blastocyst
6
Genetic Laboratory www.invictagenetics.com The impact of next-generation sequencing (NGS) preimplantation genetic diagnosis (PGD) on pregnancy rate after frozen blastocyst embryo transfer. Sebastian Pukszta 1 , Krzysztof Łukaszuk 1,2,3 , Celina Cybulska 1 , Joanna Liss 1 , Łukasz Płóciennik 1 , Waldemar Kuczyński 4,5 , Lucyna Wójcicka 3 , Patrycja Kulwikowska 1,3 , Judyta Zabielska 1,3 Study question Assessment of pregnancy rate after comprehensive chromosome screening using next-generation sequencing-based preimplantation genetic diagnosis (NGS PGD) of trophectoderm in frozen blastocyst transfer. 1 INVICTA, Fertility and Reproductive Centre, Gdansk, Poland; 2 INVICTA, Fertility and Reproductive Centre, Warsaw, Poland; 3 Department of Nursing, Medical University, Gdansk, Poland; 4 Centre for Reproductive Medicine KRIOBANK, 15-879 Białystok, Poland; 5 Department of Gynecology and Oncological Gynecology, Medical University, 15-276 Białystok, Poland The trial is registered on www.actrn. org.au with the number: ACTRN12614001037695
-
Upload
invicta-genetics -
Category
Health & Medicine
-
view
54 -
download
1
Transcript of Invicta eshre-poster-pregnancy rate after frozen blastocyst
Genetic Laboratory
www.invictagenetics.com
The impact of next-generation sequencing (NGS) preimplantation genetic diagnosis (PGD) on pregnancy rate after frozen blastocyst embryo transfer.Sebastian Pukszta1, Krzysztof Łukaszuk1,2,3, Celina Cybulska1, Joanna Liss1, Łukasz Płóciennik1, Waldemar Kuczyński4,5, Lucyna Wójcicka3, Patrycja Kulwikowska1,3, Judyta Zabielska1,3
Study questionAssessment of pregnancy rate after comprehensive chromosome screening using next-generation sequencing-based preimplantation genetic diagnosis (NGS PGD) of trophectoderm in frozen blastocyst transfer.
1 INVICTA, Fertility and Reproductive Centre, Gdansk, Poland; 2 INVICTA, Fertility and Reproductive Centre, Warsaw, Poland; 3 Department of Nursing, Medical University, Gdansk, Poland; 4 Centre for Reproductive Medicine KRIOBANK, 15-879 Białystok, Poland; 5 Department of Gynecology and Oncological Gynecology, Medical University, 15-276 Białystok, Poland
The trial is registered on www.actrn. org.au with the number: ACTRN12614001037695
Genetic Laboratory
www.invictagenetics.com
Summary answerWe confirm that NGS can be applied clinically for the purpose of detecting aneuploidy in human preimplantation embryos. Furthermore, data from this trial indicated that trophectoderm biopsy followed by frozen transfer of euploid embryos was associated with improvement in implantation and pregnancy rates.
What is known alreadyCurrently used PGD methods of aneuploidy screening have been reported to improve pregnancy rates. However, most of them are based on low-density array comparative genomic hybridisation (aCGH), with results based on less than 2700 probes. New technical possibilities, such as next-generation sequencing (NGS) methods, have already shown promise of improved genetic diagnostics in fresh cycles (1).
Genetic Laboratory
www.invictagenetics.com
Study design, size, durationProspective case control study included analysis of results from 102 embryos obtained from 34 patients (mean age 34) performed between September 2014 and November 2014 at INVICTA Fertility Centre, Poland.
Participants/materials, setting, methodsTrophectoderm biopsy was performed for the study group embryos. Next generation sequencing with Torrent Suite Software was used for chromosome copy number variation analysis.
Genetic Laboratory
www.invictagenetics.com
Fig.1 Examplary result from chip 316.
Genetic Laboratory
www.invictagenetics.com
Main results and the role of chanceWe transferred 41 vitrified blastocysts during frozen embryo transfer in the investigated group and 40 in the control group, resulting in a total of 18 embryos implanted in the PGD group and 9 in the control group. The primary outcome measure of clinical pregnancy rate per transfer was approximately 40 percentage points higher in the PGD group compared to the control group (59.3% vs. 20.0%, respectively; p<0.002). The difference in the implantation rate (secondary outcome measure) was greater than 20 percentage points (43.9% vs. 22.5%; p<0.08)
0
10
20
30
40
50
60
70
Clinical Pregnancy Implantation Spontanous abortion
Rat
e (%
)
Frozen embryo transfer
PGD
No PGD
p=0.08
p=0.06
p=0.06
Genetic Laboratory
www.invictagenetics.com
INVICTA Genetic Laboratoryul. Trzy Lipy 3, 80-172 Gdansk, Poland, T: +48 58 58 58 804, E: [email protected]; W: www.invictagenetics.com
About INVICTA Genetic LaboratoryINVICTA is an experienced genetics laboratory (since 2000)
offering wide range Preimplantation Genetic Diagnosis testing using state of art Next Generation Sequencing (NGS) techniques.
Wider implications of the findings: These findings suggest that NGS may be a useful tool for embryo selection that gives normal embryos priority for transfer. NGS technology allows personalisation of the method and therefore could be used for all cases in which PGD is indicated.
References:1. Łukaszuk K, Pukszta S, Wells D, et al. Routine use of next-generation sequencing for preimplantation genetic diagnosis of blastomeres obtained from embryos on day 3 in fresh in vitro fertilization cycles. Fertil Steril. 2015:1-6. doi:10.1016/j.fertnstert.2014.12.123.
